The capital return plan (up to ~$230M) and the Moderna settlement cash provide a significant floor for the stock. Monitor for the specific form of share repurchases (tender offer vs open market) and any updates on the Pfizer/BioNTech LNP lawsuits, which could unlock additional value. The operational quarter is irrelevant, trade on the capital allocation and litigation catalysts.
Drugs in focus
ABUS drug pipeline →AB-101
● Neutral Named in this press release- Impact
- Phase
- Phase 1a/1b
- Time to market
- AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
- Next catalyst
- None dated
What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $4.59entry
- T+1 · 3mo ago −0.22%α −0.92% · $4.58
- T+5 · 3mo ago +8.50%α +8.94% · $4.98
- T+20 · 2mo ago +11.55%α +13.44% · $5.12
- T+60 · 12d ago −20.04%α −14.93% · $3.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arbutus Biopharma reported Q2 2026 revenue of $1.0M (down from $10.7M YoY due to the prior year's Qilu partnership revenue recognition) and a net loss of $5.1M (-$0.03 EPS), in line with consensus. The quarter was overshadowed by the receipt of $178.4M from the Moderna settlement in July and a plan to return up to ~$230M to shareholders via share repurchases, alongside new LNP patent lawsuits against Pfizer/BioNTech. The stock will move on the capital return plan and litigation catalysts, not the operational results.
Key Financial Metrics
Key Facts
- Received $178.4M from Moderna settlement in July 2026 as share of $950M noncontingent payment
- Plans to return up to ~$230M to shareholders via share repurchases, potentially including a Dutch Auction tender offer
- Filed three international LNP patent lawsuits against Pfizer/BioNTech across 21 countries
- Q2 2026 revenue $1.0M vs $10.7M YoY; net loss $5.1M (-$0.03 EPS) vs net income $2.5M ($0.01 EPS) YoY
- Cash and marketable securities $92.6M as of June 30, 2026, plus $179.4M receivable from Genevant license
- FDA Fast Track designation for imdusiran in chronic hepatitis B; alignment on Phase 2b trial design
Financial Impact
Capital return of up to ~$230M (25% of current market cap) plus $178.4M cash infusion from Moderna settlement
Risk Factors
- Capital return plan is subject to board approval and may not occur in Q3 2026 or at all
- Pfizer/BioNTech lawsuits face uncertain outcomes and could be protracted
- Imdusiran Phase 2b trial may not meet endpoints or receive regulatory approval
- Contingent $1.3B Moderna payment depends on appellate ruling on 28 U.S.C. §1498
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343555 |
Track record
25 reports on ABUS
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +7.42% at T+60 after the May 13, 2026 report. 5 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
- Nov 10, 20266d ago Press Release Neutral 4/10 No price data
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
- Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers